Alongside Geisinger's corporate venturing unit in the round were venture capital firms Novitas Capital and the Pittsburgh Life Science Greenhouse.
Geisinger Health System, a US-based medical services provider, has co-led the series A round for Cernostics, which helps diagnose cancer.
Alongside Geisinger’s corporate venturing unit in the round were venture capital firms Novitas Capital and the Pittsburgh Life Science Greenhouse.
Lansing Taylor, chief executive of Cellumen and chairman of Cernostics, said: "Cernostics was founded as a spin-off of Cellumen in 2008 to apply predictive science to tissue-based diagnostics using panels of fluorescence-labeled biomarkers and informatics. We are pleased to…
